J Clin Oncol: Long-term efficacy of Selpercatinib in patients with RET fusion-positive NSCLC

Selpercatinib is a first-line highly selective RET kinase inhibitor with potent CNS activity approved for the treatment of non-small cell lung cancer (NSCLC)
with positive RET fusion.
In the LIBRETTO-001 trial, Selpercatinib demonstrated long-lasting antitumor activity, including intracranial efficacy
.

In this paper, researchers have updated their analysis
of the long-term efficacy and safety of Selpercatinib in RET fusion-positive NSCLC.

The LIBRETTO-001 trial was a single-group, open-label, phase I/II trial that enrolled 69 patients with initially treated RET fusion-positive NSCLC and 247 patients with REET-fusion-positive NSCLC who had received platinum-based chemotherapy
.
The primary endpoint was the objective response rate
.
Secondary endpoints included duration of remission, progression-free survival, overall survival, and safety
.

In the initial treatment of patients, the objective response rate is 84%, and 6% of patients have achieved complete remission
.

Among patients who had received platinum-based chemotherapy, the objective response rate was 61%, and 7% of patients achieved complete remission
.

Among the 26 patients with neurologic metastases at baseline, the objective intracranial response rate was 85%, including 27% of complete response
.

Overall, extended follow-up analysis of this large cohort study showed that Selpercatinib consistently demonstrated durable and robust therapeutic activity, including intracranial antitumor activity
, in previously treated and untreated patients with RET fusion-positive NSCLC.

Original Source:

Alexander Drilon, et al.